The early diagnosis of Alzheimer’s disease: defining the patient journey for a paradigm shift Alzheimer’s disease (AD) is the most common form of dementia, affecting millions of people worldwide and causing major personal and family distress and socio-economic burden. The presentation of AD encompasses a continuum that extends from asymptomatic individuals with pathological evidence of AD to patients with mild cognitive impairment (MCI) due to AD and finally patients with AD dementia. Pathological hallmarks of AD, β-amyloid plaques and neurofibrillary tangles may be detectable in the brain decades before clinical symptoms. In this context substantial technological advances in neuroimaging (MRI and PET) and CSF analysis allowed the development of biomarkers related to neurodegeneration, cerebral β-amyloid deposition, and tau-related pathology, increasing diagnostic accuracy and favoring the identification of early AD patients. A timely and accurate diagnosis in the early stages of disease is critical for prognosis and advanced-care planning, which requires coordination between the patient, caregivers, family members, HCPs, specialists, social services and payers. During the “Meet the Expert” the crucial theme of AD early diagnosis will be presented, discussing different steps of diagnostic journey including the relevance of clinical and biomarker assessments. Key learnings, implications and recommendations will be shared on how to improve patient journey, supporting paradigm shift in AD.

Management of patients with LGS on GW cannabidiol: expert clinical cases Please join us for this virtual Meet the Experts Session, which brings together a panel of experts to present and discuss clinical cases on the management of patients with Lennox-Gastaut Syndrome on GW cannabidiol. Professor Antonietta Coppola will introduce the session and present her experience of initiating GW cannabidiol in a 29-year old female patient receiving treatment with other cannabis-based products. Professor Angela Kaindl will present the treatment history and initiation of GW cannabidiol in a 9-year old male patient. Professor Sameer Zuberi will conclude the case presentations by describing polytherapy and monitoring requirements in a 4-year old female patient. The Experts will then discuss their cases and answer questions from the audience in a live Q&A, chaired by Professor Antonietta Coppola. We look forward to receiving your questions to support an interactive and engaging session! This session is intended for an HCP or prescriber audience only and is organized and funded by GW Pharmaceuticals. GW cannabidiol information is in line with the EMA product license. The international prescribing information will be available at this session and from the GW virtual exhibition booth on the congress website. The indication may differ in your country; please refer to the local prescribing information. Job code: VV-MED- 22753 Date of preparation: August 2021

Satralizumab: a new opportunity for neuroimmunological disorders Neuroimmunological diseases are chronic diseases with an evolutionary burden of disabilities, often unpredictable and affect young adults influencing personal and professional life choices. Among these, we can include the neuromyelitis optic spectrum disorder (NMOSD), a rare disease with still a high therapeutic need to satisfy. Satraliizumab, a monoclonal antibody targeting the IL6 receptor, represents an important therapeutic innovation because it targets a critical proinflammatory cytokine, fundamental for the immunopathogenesis of NMOSD and also for other neuroimmunological pathologies including Myasthenia Gravis, Autoimmune Encephalitis and MOGAD.